ReviewSeminars in immunopathology2019
Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease).
Review in Seminars in immunopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 67 citations in OpenAlex.
- The sliding cupping therapy as an alternative strategy for treating plaque psoriasis: A randomized controlled trial.Medicine · 2026Trial
- Secondary Exposure to IMQ or Irritants Enhances Psoriasiform Recurrence Through Inflammatory Memory.Inflammation · 2026Article
- Effects of tildrakizumab on circulating T cells in autoreactive psoriatic patients.Frontiers in immunology · 2026Article
- From clinical remission to biological stability in psoriasis: an antigen-blood-tissue framework for relapse stratification.Frontiers in immunology · 2026Review
- Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis.Lasers in medical science · 2025Observational
- Psoriasis, stem cells, and obesity: metabolic exploration for therapeutics.Journal of medicine and life · 2025Review
- Early Neutrophil Activation in Psoriatic Skin at Relapse Following Dead Sea Climatotherapy.Experimental dermatology · 2025Article
- Interventions in cytokine signaling: novel horizons for psoriasis treatment.Frontiers in immunology · 2025Review
- Bilayered skin equivalent mimicking psoriasis as predictive tool for preclinical treatment studies.Communications biology · 2024Article
- Secukinumab and Dead Sea Climatotherapy Impact Resolved Psoriasis Skin Differently Potentially Affecting Disease Memory.International journal of molecular sciences · 2024Article
- Inflammatory Memory in Epidermal Stem Cells - A New Strategy for Recurrent Inflammatory Skin Diseases.Journal of inflammation research · 2024Review
- Article
- Abnormal basement membrane results in increased keratinocyte-derived periostin expression in psoriasis similar to wound healing.Scientific reports · 2023Article
- Topical proactive therapy in dermatology. A scoping review.Postepy dermatologii i alergologii · 2023Article
- Does molecular scarring in psoriasis exist? A review of the literature.Postepy dermatologii i alergologii · 2023Review
- Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab.ImmunoHorizons · 2023Article
- Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.International journal of dermatology · 2022Article
- Multiple Cytokine Analysis of Th1/Th2/Th9/Th17/Th22/Treg Cytokine Pathway for Individual Immune Profile Assessment in Patients with Psoriasis.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Comparison of Th1 and Th17 Inflammatory Cytokine Profiles Between Chronic Plaque and Acute Guttate Psoriasis.Annals of dermatology · 2022Article
- The biological basis of disease recurrence in psoriasis: a historical perspective and current models.The British journal of dermatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory skin disease that involves numerous types of immune cells and cytokines resulting in an inflammatory feedback loop and hyperproliferation of the epidermis. A more detailed understanding of the underlying pathophysiology has revolutionized anti-psoriatic treatment and led to the development of various new drugs targeting key inflammatory cytokines such as IL-17A and IL-23. Successfully treated psoriatic lesions often resolve completely, leaving nothing visible to the naked eye. However, such lesions tend to recur within months at the exact same body sites. What is left behind at the cellular and molecular levels that potentially reinitiates psoriasis? Here, we elucidate the cellular and molecular "scar" and its imprints left after clinical resolution of psoriasis treated with anti-TNFα, anti-IL-17, or anti-IL-23 antibodies or phototherapy. Hidden cytokine stores and remaining tissue-resident memory T cells (TRMs) might hold the clue for disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.